Nielsen on Raptors: You make the call

It was an odd ending to an odd game.

After spending a good portion of Sunday’s game with the Lakers fighting back to take the lead after a large first-quarter deficit, the Toronto Raptors had two chances to beat Los Angeles in the final five seconds and failed both times. The final result ended up being a 94-92 Lakers victory.

On the first opportunity, with the Lakers leading by a point and only 4.2 seconds remaining on the game-clock, Raptors coach Dwane Casey inserted Rasual Butler into the game to inbound the ball and the team was handed a five-second violation.

If you’re a Raptors player, coach or fan you could argue that it was an awfully fast count – especially for a call you rarely see made in the NBA.

“I asked (referee Scott Foster) to count out loud and he did,” Butler explained. “I heard four, I turned to call a timeout and he felt like it was five seconds.”

Butler said he was disappointed, “You always want to get your team a shot to win the game.”

Casey was unwilling to talk about the referee’s decision after the game.

“I like my money, what little money I make I like it, so I’m not going to comment on it,” Casey said, eluding to the fact that he would be fined by the NBA if he said something about the officiating.

(By the way, shouldn’t the officials have to answer to the media after games for moments just like these?)

Now of course, if you are on the Lakers’ side, you would see the call as the correct one.

Lakers star Kobe Bryant said he wasn’t surprised by the call. “I didn’t go to college but I can count. It was five seconds — good defence on our part.”

Some might ask: why was Butler inserted into the game to make the pass as he had not seen any action in the game whatsoever until that point?

“He’s our best inbound passer because what teams normally do is put their longest guy on the ball. He’s our best inbounds passer. He sees the situation as a veteran player.”

What makes that answer a little perplexing is that the Raptors found themselves in a similar situation soon after when they quickly fouled Bryant who promptly missed one of his first free throws, leaving the Raptors facing a two-point deficit with 3.7 seconds remaining. They still had a chance to win or at least send the game to overtime.

The Raptors were given the ball at halfcourt and this time, sure-handed Jose Calderon was given the responsibility of getting the ball inbounds.

Not to play Devil’s Advocate, but why was Butler not taking the second inbounds as well? Especially considering the fact that Calderon had scored a career-best 30 points on the night?

(Ok. I played Devil’s Advocate there for a moment.)

Calderon was able to get the second inbound pass into DeMar Derozan, who took a step-back three and air-balled it.

The shot selection was another interesting choice as the Raptors only needed a deuce to even the score but in DeRozan’s defence, he had a hand in his face as he launched the shot.

A few funny moments from around the ACC this weekend:

1. After Friday’s loss to the Raptors, a few reporters were still in the Boston Celtics locker room waiting to talk to Rajon Rondo when his teammate Paul Pierce had a recommendation for the scribes to watch the documentary Forks Over Knives. He said it would change our lives.

When asked if it had changed his life, Pierce responded by saying, “No. But it made me think.”

2. Before Sunday’s loss to the Lakers, Casey said that Andrea Bargnani has been doing a lot of work in the pool. Casey’s new nickname for the big Italian is “Flipper”.

A reporter asked for a report on Bargnani’s swimming skills and Casey said, “It’s better than mine because I can’t swim a lick.”

3. After the game on Sunday, Lakers forward Luke Walton offered a slice of pepperoni pizza to Metta World Peace to which he politely declined.

Walton tried to convince him to grab a slice by saying, “It’s good for you.”

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Most Watched Today